Filter by
Documents (167)
RSSShowing results 140 to 160
Report to monitor the European clinical trials environment (1-30 June 2023, edition 15)
Report to monitor the European clinical trials environment (1-31 May 2023, edition 14)
Report to monitor the European clinical trials environment (1-30 April 2023, edition 13)
Report to monitor the European clinical trials environment (1-31 March 2023, edition 12)
Report to monitor the European clinical trials environment (1-28 February 2023, edition 11)
Report to monitor the European clinical trials environment (1-31 January 2023, edition 10)
Report to monitor the European clinical trials environment (1-31 December 2022, edition 9)
Report to monitor the European clinical trials environment (1-30 November 2022, edition 8)
Report to monitor the European clinical trials environment (1-31 October 2022, edition 7)
Report to monitor the European clinical trials environment (1-30 September 2022, edition 6)
Report to monitor the European clinical trials environment (1-31 August 2022, edition 5)
Report to monitor the European clinical trials environment (1-31 July 2022, edition 4)
Report to monitor the European clinical trials environment (1-30 June 2022, edition 3)
Report to monitor the European clinical trials environment (1-31 May 2022, edition 2)
Report to monitor the European clinical trials environment (31 January – 30 April 2022, edition 1)
Complex clinical trials – questions and answers
Highlighted
Recommendation paper on decentralised elements in clinical trials
Annex I - Guidance document on how to approach the protection of personal data and commercially confidential information while using the Clinical Trials Information System (CTIS) Version 2.2
Guidance document on how to approach the protection of personal data and commercially confidential information while using the Clinical Trials Information System (CTIS) Version 2.2
Outcome of public consultation on ACT EU MSP participation and priorities for discussion
The report on the outcome of a public consultation where the European Medicines Agency invited stakeholders to provide input on the ACT EU MSP concept paper, priority topics for the MSP and to express their interest in participating.
